A study to investigate safety of INT2104 infusions in participants aged 18 years of age and older who have B-cell cancers that came back after previous treatment [INVISE]

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509132-26-00

Acronym

INT2104-101

Enrollment

Registered

2024-12-12

Start date

2025-08-08

Completion date

Unknown

Last updated

2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory/Relapsing B-Cell Malignancies

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026